Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A | P35348 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 4/20 | 0.42 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.42 |
| ▸ | EGLN1 | Q9GZT9 | 4/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.41 |
| ▸ | KDM5C | P41229 | 3/20 | 0.41 |
| ▸ | PHF8 | Q9UPP1 | 3/20 | 0.41 |
| ▸ | KDM2A | Q9Y2K7 | 3/20 | 0.41 |
| ▸ | KDM6B | O15054 | 2/20 | 0.41 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.38 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.38 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.38 |
| ▸ | ECE1 | P42892 | 2/20 | 0.37 |
| ▸ | BBOX1 | O75936 | 2/20 | 0.35 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL8654453 | 0.98 | ADRA1A (0.43) | ADRA1ALMNASLC15A2EGLN1KDM4E | |
| Water SCHEMBL7773341 | 0.98 | ADRA1A (0.43) | ADRA1ALMNASLC15A2EGLN1KDM4E | |
| SCHEMBL5596643 | 0.86 | ADRA1A (0.52) | ADRA1ALMNASLC22A6TSHRKMT2A | |
| SCHEMBL16360052 | 0.78 | LMNA (0.53) | LMNASLC15A2EGLN1KDM4EKDM5C | |
| SCHEMBL7396316 | 0.75 | ECE1 (0.41) | LMNAEGLN1KDM4EKDM5CPHF8 | |
| SCHEMBL11015165 | 0.75 | LMNA (0.38) | LMNAEGLN1KDM4EKDM5CPHF8 | |
| SCHEMBL7398735 | 0.75 | ECE1 (0.41) | LMNAEGLN1KDM4EKDM5CPHF8 | |
| SCHEMBL7401741 | 0.75 | LMNA (0.36) | ADRA1ALMNASLC15A2EGLN1KDM4E | |
| SCHEMBL12308944 | 0.75 | ALDH1A1 (0.41) | KDM4E | |
| SCHEMBL4864289 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7309719-B1 | Storage stability; gabapentin and pregabalin, and neutral alpha -amino acid | WARNER LAMBERT COMPANY, LLC (US) | 2007-12-18 | — | — | US | disclosed |
| EP-1077692-B1 | AMINO ACID STABILIZED GABAPENTIN AND PREGABALIN PREPARATIONS AND PROCESS FOR PREPARING THE SAME | WARNER LAMBERT CO (US) | 2004-07-28 | — | — | EP | disclosed |
| US-20010051730-A1 | Beta-alanine derivative and a process for the preparation thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-12-13 | — | — | US | disclosed |
| EP-1121346-A1 | NEW PROCESSES FOR PRODUCING BETA-ALANINE DERIVATIVE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-08-08 | — | — | EP | disclosed |
| EP-1077692-A1 | AMINO ACID STABILIZED GABAPENTIN AND PREGABALIN PREPARATIONS AND PROCESS FOR PREPARING THE SAME | Warner-Lambert Company LLC (US) | 2001-02-28 | — | — | EP | disclosed |
| WO-1999059573-A9 | STABILIZED PHARMACEUTICAL PREPARATIONS OF GAMMA-AMINOBUTYRIC ACID DERIVATIVES AND PROCESS FOR PREPARING THE SAME | WARNER LAMBERT CO (US) | 2000-05-04 | — | — | WO | disclosed |
| WO-2000021932-A1 | NEW PROCESSES FOR PRODUCING β-ALANINE DERIVATIVE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-04-20 | — | — | WO | disclosed |
| WO-1999059573-A1 | STABILIZED PHARMACEUTICAL PREPARATIONS OF GAMMA-AMINOBUTYRIC ACID DERIVATIVES AND PROCESS FOR PREPARING THE SAME | WARNER-LAMBERT COMPANY (US) | 1999-11-25 | — | — | WO | disclosed |
| EP-0888302-A1 | N- (R)-1- 3-(4-PIPERIDYL)PROPIONYL-3-PIPERIDYLCARBONYL]-2(S)-ACETYLAMINO-BETA-ALANINE AS FIBRINOGEN RECEPTOR ANTAGONIST | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1999-01-07 | — | — | EP | disclosed |
| EP-0869944-A1 | N-ACYLPIPERIDINYLCARBONYLAMINOCARBOXYLIC ACIDS AND THEIR USE AS GLYCOPROTEIN IIB/IIa ANTAGONISTS AND FIBRINOGEN-BLOOD PLATELETS BINDING INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-10-14 | — | — | EP | disclosed |
| WO-1997033869-A1 | N-[(R)-1-{3-(4-PIPERIDYL)PROPIONYL-3-PIPERIDYLCARBONYL]-2(S)-ACETYLAMINO-BETA-ALANINE AS FIBRINOGEN RECEPTOR ANTAGONIST | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1997-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010051730-A1 | Beta-alanine derivative and a process for the preparation thereof | F13B, FGB, TGFB1 | ADRA1A 293/4885LMNA 899/4885SLC15A2 1976/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.